Headline Expenditure Projections
- Pharmaceuticals: EUR1.67bn (USD2.20bn) in 2013 to EUR1.68bn (USD2.13bn) in 2014; 0.6% in local currency terms and -3.2% in US dollar terms. Figures in line with Q214.
- Healthcare: EUR6.00bn (USD7.92bn) in 2013 to EUR6.07bn (USD7.71bn) in 2014; 1.2% in local currency terms and -2.6% in US dollar terms. Slight revision downward owing to macroeconomic backdrop.
Slovakia's Risk rating indicates the country has one of the best business environments in the Central and Eastern European region, although its ranking is moderated by its less-than-stellar rewards score. Consequently, Slovakia has a RRR score of 55.2 out of 100, making it now the sixth most attractive pharmaceutical market in Central and Eastern Europe. This means the country has dropped by one position from Q214.
Key Trends And Developments
- In May 2014, Slovakia's health minister Zuzana Zvolenska stated that state-run hospitals should pay off their mounting debts at their own expense. Zvolenska added that any help from the state may only be supplementary. The government will address a report on the indebtedness of healthcare facilities in 2013 during a press conference.
- In 2013, around 13 teaching and university...
The Slovakia Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.
BMI's Slovakia Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Slovak pharmaceutical and healthcare industry.Key Benefits
CoverageBMI Industry View & Industry SWOT
- Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Slovakia to test other views - a key input for successful budgeting and strategic business planning in the Slovak pharmaceutical and healthcare market.
- Target business opportunities and risks in the Slovak pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Slovakia.
- Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.
An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.Market Summary
Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.Regulatory Regime
Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.Industry Developments
Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.BMI Industry Forecasts
Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:
Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)
Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)
Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)
Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)
OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)
Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)
Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.Competitive Landscape
The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.Company Profiles
Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.
The Slovakian government is planning to allocate EUR278mn (USD386.7mn) in EU funding to develop healthcare and medical infrastructure in Slovakia over the 2014-2020 period, reports news agency TASR. The government added that after adding contributions from the state budget, the total funds that have been allocated for developing healthcare infrastructure will be EUR300mn (USD417.3mn). The government plans to allocate these funds to projects in large university hospitals and developing integrated outpatient healthcare facilities in the country. Slovakia continues to be an attractive pharmaceutical market for large multi-nationals because it generally offers significant potential as a location for pharmaceutical research.